Business · 25/02/2019Updated: 10/17/2026 · 1 min read
FDA Reopens Comment Period for Proposed Rule on Institutional Review Board Waiver or Alteration of Informed Consent
Summary
The Food and Drug Administration is reopening the comment period for a proposed rule related to Institutional Review Board waiver or alteration of informed consent for minimal risk clinical investigations, following technical issues with the Federal eRulemaking Portal.